Beranda › Kanker Paru › New Hampshire
Uji klinis Kanker Paru di New Hampshire
12 studi untuk Kanker Paru mencari peserta di lokasi di New Hampshire.
Kota di New Hampshire
Teks studi resmi (Bahasa Inggris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- The Dana-Farber Cancer Institute at Londonderry, Londonderry
Menerima pesertaFase 3
Usia 70 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06096844Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Dartmouth-Hitchcock Medical Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06881784A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0467, Lebanon
- Local Institution - 0600, Manchester
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07063745A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Dartmouth-Hitchcock Medical Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- New Hampshire Oncology Hematology PA-Concord, Concord
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
- Solinsky Center for Cancer Care, Manchester
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- Dartmouth Hitchcock Medical Center, Lebanon
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT05948865Healthy Homes Study
- Dartmouth Cancer Center, Lebanon
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jan 2026 · NCT05833334Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.